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Systemic lupus erythematosus (SLE) is a rare immunological disorder where genetic factors 
are considered important in causation. Monogenic lupus has been associated with around 30 
genotypes in humans, and 60 in mice; whilst genome-wide association studies have 
identified more than 90 risk loci. We aimed to determine the genetic contribution of rare and 
predicted pathogenic gene variants in a population of unselected cases of childhood-onset 




We designed a next generation sequencing (NGS) panel comprising 147 genes, including all 
known lupus causing (KLC) genes in humans, and potentially lupus causing (PLC) genes 
identified through GWAS and animal models. We screened 117 probands fulfilling ACR 
criteria for SLE, ascertained through British and French cohorts of cSLE, and compared 
these data with those of 791 ethnically matched controls from the 1000 Genomes Project, 




Mendelian genotypes were confirmed in eight probands, involving mutations in C1QA, C1QC 
C2, DNASE1L3 and IKZF1. Seven additional patients carried heterozygous mutations in 
complement or type I interferon associated autosomal recessive genes, with decreased 
levels of the encoded proteins recorded in two patients. Rare, predicted damaging variants 
were significantly enriched in the cSLE cohort compared to controls; 25% of SLE probands 
versus 4.6% of controls were identified to harbour at least one rare, predicted damaging 




Inborn errors of immunity account for 7% of cSLE, with defects of innate immunity 
representing the main monogenic contribution. An accumulation of rare, predicted damaging 
variants in SLE-associated genes may contribute to disease expression and clinical 
heterogeneity.  
 
Keywords: Monogenic lupus; paediatric rheumatology; genetics; innate immunity; 
complement deficiency 
 




The term systemic lupus erythematosus (SLE) describes a rare, heterogeneous set of 
phenotypes characterized by the presence of autoantibodies targeting nuclear autoantigens 
and type I interferon upregulation. Familial aggregation and higher concordance rates 
between monozygotic compared to dizygotic twins suggest a major hereditary component to 
pathogenesis1. Genome-wide association studies (GWAS) have identified more than 90 SLE-
associated loci2. GWAS defined variants are common, confer small effects on disease 
susceptibility and typically fall outside of coding regions. In contrast, monogenic forms of 
SLE, of which almost 30 have been described in humans, and greater than 60 in mice3, 
involve highly penetrant rare variants in protein encoding DNA4.  
 
Mendelian forms of disease can help define the involvement of discrete pathways in 
pathogenesis. For example, both classical complement gene mutations and DNASE1L3 
deficiency highlight the importance of efferocytosis in lupus pathology5,6, whilst the relevance 
of type I interferon signalling to SLE is underlined by the association with the Mendelian type 
I interferonopathies7,8. Finally, B cells are a key player in lupus causation9, with PKCδ 
deficiency the first described B cell related form of monogenic lupus10, and heterozygous 
germline mutations in IKZF1, encoding IKAROS, a B cell transcription factor, a cause of 
autoimmunity including SLE11.  
 
Recent sequencing studies suggest a false dichotomy in categorizing diseases according to 
strict complex or Mendelian models, an alternative possibility highlighting the importance of 
combinations of small numbers of rare variants promoting disease in a single individual and 
at a population level12. Immune responses are variable in humans, with up to 40% of this 
diversity estimated to be explained by genetic variation13. In association with environmental 
factors, such genetic polymorphisms may promote tolerance breakdown14, as exemplified by 
the lupus phenotype.  
 
Here, we describe a large-scale molecular analysis of childhood-onset SLE (cSLE), 
indicating a mutational spectrum directly causing, or strongly influencing, pathogenesis.  
 




We identified 117 unrelated probands from the UK Juvenile-onset SLE (JSLE)15 and French 
SLE GENIAL cohorts fulfilling American College of Rheumatology (ACR) criteria for lupus, 
diagnosed before the age of 16 years. The study was approved by the relevant ethics 
committees (see the Appendix for further details). The combined cohort comprised the 
following ethnicities: European (50%), African (33%) and South Asian (16%), classified 




To identify genetic variations potentially responsible for SLE, we selected a set of genes 
based on: i) known Mendelian forms of lupus (‘known lupus causing’ – KLC - genes; n = 28), 
some also detected by GWAS and/or in murine studies (table S1); ii) defined causes of 
monogenic lupus in mouse models (n = 62) and/or genes demonstrating an association with 
SLE identified through GWAS (n = 67), with 11 genes common to both. The latter group are 
referred to as ‘putative lupus causing’ (PLC) genes (table S2). Defined as of 2013 when the 
study was initiated, this set comprised 147 genes in total.  
 
DNA sequencing, variant discovery and filtering 
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Details of our sequencing protocols and variant analyses are provided in the Appendix. In 
brief, targeted enrichment and sequencing of the coding regions of 147 gene panel was 
undertaken using DNA extracted from peripheral blood. Single nucleotide variants (SNV) and 
indels were identified according to strict bioinformatic protocols, aligned with 1000 Genomes 
Project (1000g) sequence sets, and variant pathogenicity assessed using SIFT, Polyphen-2 
and Combined Annotation Dependent Depletion (CADD) v1.3 scores. A rarity filter 
considered SNVs according to their population frequencies within the Exome Aggregation 
Consortium (ExAC) dataset, employing 1% and 0.1% in the case of putative biallelic 
mutations, or 0.01% and 0.001% for heterozygous variants in the case of indels or SNVs 
respectively, as our thresholds (threshold (heterozygous) = threshold (homozygous)2 i.e. 10-4 
for indels and 10-6 for SNVs). A pathogenicity filter considered selected indels with a CADD 
score higher than 15, and SNVs according to the formula: CADD score ≥ 15 AND sift score ≤ 
0.05 AND Polyphen 2 score ≥ 0.9. A cartoon of the characterization of different sequence 
variants is given in figure S1 in the Appendix. For the FREX consortium and UK controls, 




Control data were derived from the 1000 Genomes Project (1000g). The healthy control 
cohort comprised 791 unrelated individuals demonstrating a similar ethnic distribution to the 
cSLE cohort (50% European, 33% African; 16% South Asian), built by random sampling 
among the 1000g sample set. Two additional control populations were ascertained through 
the FREX consortium, a French-specific database containing the exome data of a reference 
control panel of 574 individuals of French ancestry (http://lysine.univ-brest.fr/FrExAC/) and a 
UK control panel: 74 adults from the north west of England, sequenced and analysed using 
exactly the same targeted exon panel, sequencing platform and filtering strategy as 
employed in the lupus cohort. Additional information is given in Appendix. 
 
In vitro assays, structural analyses 
 
Details of in vitro experiments, structural studies and protein interaction network construction 




Fisher's exact test was used to compare the frequencies of variants in the control and cSLE 
cohorts. Data normality was assessed using a Shapiro-Wilk test and quantile-quantile plots. 
The mean of SNPs per individual was compared between control and cSLE cohorts using a 
Mann-Whitney U test (Wilcoxon rank-sum test). P-values were adjusted using the Bonferroni 
correction where appropriate. Odd ratios were calculated using the standard formula, with 
S1/2 the number of variants that passed a filter and F1/2 those which failed for the two 
groups compared (OR = S1*F2 / F1*S2). 
 
Role of the funding source 
 
The funders were represented by European or National academic funding agencies. The 
funders had no role in the study design, data collection, data analysis, data interpretation or 
writing of the report. The views expressed in this publication are those of the authors and not 
necessarily those of the agencies. The corresponding authors had final responsibility for the 







Our patient cohort demonstrated a median age at disease onset of 9 (range 1.8 - 16) years 
and sex ratio of 25/92 (male:female = 1:3.7) (figure 1B, table S3). Similar to previous studies 
of cSLE, major organ involvement was frequent, with renal and cerebral disease noted in 
59% and 23% of individuals respectively. A family history of lupus was reported in 20% of 
cases (first or second degree relatives).  
 
Next generation sequencing identified a total of 30,955 variants in the 147 KLC and PLC 
genes across 117 patients (figures 1C, 1D) in the protein coding part of the gene 
(Supplemental Figure S1). Filtering according to the strategy described above was used to 
select for very rare variants, allowing us to exclude 99.95% of the initially identified 
polymorphisms. A similar strategy was applied to the control cohort of 791 ethnically 
matched individuals from the 1000g (SNVs and indels) and from the FREX consortium 
(SNVs) (figure 1E). An additional confirmatory cohort was generated from UK control panel: 
74 adults from the north west of England sequenced and analysed using exactly the same 
targeted exon panel, sequencing platform and filtering strategy as employed in the lupus 
cohort. 
 
Characterization of Mendelian genotypes 
 
After filtering, 15 unrelated probands were identified to harbour a total of 14 either 
heterozygous or biallelic variants in 11 KLC genes (table 1), relating to components of the 
classical complement pathway (C1QA, C1QC, C2, C3, C8B, C9), DNASE1L3 deficiency 
(DNASE1L3), type I interferonopathies (TREX1, RNASEH2C, ACP5) or B-cell dysfunction 
(IKZF1). Ten of these 14 variants were novel (i.e. not seen in publicly available databases), 
with five having been reported previously as disease causing.  
 
Segregation was compatible with autosomal recessive inheritance due to complement 
deficiency in six pedigrees. Biallelic mutations in either C1QC or C1QA were identified in 
three families (figure 2A). In silico structural analysis of C1qC predicted that the p.Gly164Ser 
substitution, already reported as pathogenic16, destabilizes the globular head of the C1q 
complement protein (figure 2B). Two other variants in C1QC and C1QA were nonsense 
mutations. C1q was undetectable in patient 1 and 2 (Pt1, Pt2) (figure 2C). Patients 4 to 6 
carried the same biallelic deletion in the C2 gene (figure 2D), previously described as a 
cause of lupus with incomplete penetrance17. CH50 and C2 levels were decreased in Pt6, 
whist C3 and C4 were normal (figure 2E).  
 
Two predicted damaging variants in DNASE1L3 were identified in Pt7, and biallelic 
inheritance confirmed by parental testing (figure 3A). The nonsense mutation has been 
reported as disease causing18, whilst the deletion of exon 5 was novel, located in the 
deoxyribonuclease domain (figure 3B) and confirmed by TAQman qPCR.  
 
Sequencing of the family of Pt8 demonstrated segregation of a novel missense IKZF1 variant 
with disease status in two additional relatives (figure 3C). A previous GWAS identified 
significant association with lupus at the IKZF1 locus19, whilst loss-of-function germline 
mutations have been recently reported to cause systemic autoimmunity and B cell 
deficiency11. Thus, IKZF1, initially considered as a PLC gene, was subsequently classified as 
a KLC gene. The p.Asp120Val IKZF1 variant is located in the first zinc finger of the protein 
(figure 3D). Confocal microscopy of NIH-3T3 cells transfected with wild type (WT) and 
mutant constructs revealed a punctate staining pattern characteristic of pericentromeric 
heterochromatin binding and localization of the WT protein, whereas the mutant protein 
exhibited diffuse nuclear staining, as previously observed for other pathogenic missense 
variants20. We also performed an electrophoretic mobility-shift assay (EMSA) using nuclear 
extract of transfected cells, and observed that the Asp120Val protein was unable to bind a 
consensus-binding sequence (similar to a previously reported mutation Arg164Gln) (figure 
3D). Finally, we transduced Granta cells with inducible lenti-vector pInducer21 (ORF-EG) 
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(Addgene) expressing either WT-IKZF1 or Asp120Val-IKZF1, and recorded a decrease of 
transcriptional activity of the mutant construct by RNAseq analysis (figure 3E, F). Notably, all 
three affected patients carrying the p.Asp120Val mutation had normal immunoglobulin levels 
and did not present features of immunodeficiency.  
 
Heterozygous variants in autosomal recessive KLC genes (Mendeliome) and PLC 
genes 
 
Seven probands were identified to carry a monoallelic, rare, predicted damaging variant in a 
KLC gene previously described to cause SLE as an autosomal recessive trait (table 2). A 
TREX1 p.Ser82Leufs*9 frameshift mutation had already been reported as disease-causing in 
Aicardi-Goutières syndrome (AGS)21 . Other predicted damaging variants were recorded in 
RNASEH2C, ACP5, C3, C8B and C9. In this group of seven patients the sex ratio was 4:3, 
similar to the subset of probands described immediately above, and differing from the overall 
composition of our cohort (figure S2). Furthermore, the mean age at onset was earlier in this 
group than in the cohort overall. Pt15, carrying a p.Ile1093Ser C3 substitution, presented 
with a phenotype characterized by early onset glomerulonephritis (lupus nephritis with C1q 
deposits) and thrombotic microangiopathy. He benefited from treatment with eculizumab and 
is still in remission after three years of therapy. C3 was undetectable on several 
assessments, representing the lowest levels recorded in the whole cSLE cohort (figure 3G). 
Heterozygous variants in C3 have been reported as possibly causal of SLE22 and evolution 
with eculizumab strongly support a causal impact of the mutation. A C9 variant was similarly 
associated with decreased protein levels in patient plasma (Pt14) (figure 3H). The C8B 
variant seen in Pt13 did not impact on plasmatic C8 concentration. The other patients were 
not available for additional investigations.   
 
Focusing on variants in PLC genes, we detected 17 rare, predicted damaging PLC variants 
in 16 additional unrelated probands (Table 2).  
 
To test in an unbiased manner if the accumulation of rare, predicted damaging heterozygous 
KLC and PLC variants was specifically associated with cSLE status, we constituted first a 
control cohort by analysing the genomic sequence data of 791 healthy individuals from the 
1000g database, ensuring a similar distribution of ethnicity to our patient group, as shown by 
the PCA analysis of the frequent (MAF>1%) SNPs (figure S3). We applied the same 
algorithm to the controls as used in our cSLE data set. In so doing, we observed a 
statistically significant excess of rare, predicted damaging variants within the cSLE 
population compared to 1000g controls after adding filtering for rarity plus pathogenicity 
(figure 4A), with an odds ratio of 17.2 (CI 95% = 3.36-90,34) in KLC genes (figure 4C). For 
PLC genes, a significant difference was also identified with the same filtering strategy  (rarity 
plus pathogenicity) (figure 4B), with an enrichment of 4.4 (CI95% = [2.02;8.18]) in the lupus 
population (figure 4C, D). These data comprised all variants in our gene panel in the SLE 
and 1000g cohort datasets, generated respectively by targeted sequencing and whole 
genome sequencing. Of note, sequence coverage was different between our in-house 
derived sequence and those of the 1000g (table S4). To further consider the comparability of 
our patient and control groups, we undertook a confirmatory analysis using data from a 
second control population (FREX Consortium)(figure 4A, 4B), demonstrating a higher 
coverage across our gene panel (table S4). Again, the overall mutational load was 
significantly increased for KLC and PLC genes in the cSLE population, with a greater odds 
ratio when considering rarity plus pathogenicity status, compared to rarity only, with an OR 
that reached 11.1 (CI95% = [2.151;57.202]) and 2.83 (CI95%=[1.398;5.735]) for KLC and 
PLC genes respectively under this latter filtering strategy (figure 4C, 4D). Coverage 
information of the variants selected from the panel are represented in supplemental table S5. 
A similar trend was also observed when we considered 74 controls from a United Kingdom 
cohort of healthy adults performed using the same panel sequencing sharing identical 
coverage and analysed with the same gene panel and filtering strategies, but the analysis did 
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not reach significance (table S6). In addition to the global evaluation of rare genetic variants, 
we tested if rare variants within the genes identified in the panel were differentially distributed 
in the lupus patients compared to controls. To do so, we performed rare variant association 
tests using the sequence Kernel association (SKAT-O) method, which combines burden and 
variance component tests and has been used to explore rare genetic variants association 
testing. We observed a higher burden of rare variants in the lupus population in three genes: 
C1QC, RNASEH2C, MECP2 and CD19 (table S7). Finally, we compared the combined 
frequency of KLC and PLC rare and predicted damaging variants per proband in the panel 
and 1000g, and identified a statistically significant increase of filtered variants in one, two and 
three genes per individual in the SLE population (figure 4E,F). Taken together, these 
mutational load and gene specific analyses suggest an enhanced contribution of rare and 




Immunoprofiling of cSLE patients has highlighted the heterogeneous nature of this 
phenotype23. Whilst the basis of such heterogeneity remains poorly defined, the identification 
of Mendelian forms of SLE related to different pathogenic mechanisms indicates that genetic 
factors are likely important. Low frequency variants are not captured by GWAS, nor do they 
confer sufficiently large effect sizes to be detected by classical linkage analysis in small 
family studies4. Meanwhile, the observation of variable penetrance and expression in 
Mendelian disorders indicates that other genes or environmental factors can impact 
phenotype. Here, we add to the understanding of germline predisposition to early-onset SLE.  
 
A major challenge of our study was to set appropriate thresholds, in terms of population 
frequency and pathogenicity prediction, in order to capture likely causal variants. Given the 
identification of unequivocal Mendelian genotypes, the algorithms we employed appear valid. 
This bioinformatics strategy also demonstrated that the distribution of filtered variants was 
not equal in ethnically matched patient and control populations. Such stringent filtering, 
leading to an enrichment for likely pathogenic alleles, risks excluding possible disease-
causing variants. For example, a p.Asp105Ala heterozygous variant in RNASEH2B, 
previously considered as causal for SLE7, was excluded using this filtering strategy (data not 
shown). As such, our results likely represent a conservative estimate of the associated high-
penetrant genetic load. 
 
Our analysis identified eight probands with mutations in KLC genes consistent with 
Mendelian causation. Complement deficiencies accounted for 5% of probands in our cohort 
and a defect of efferocytosis is also relevant in DNASE1L3 deficiency6. Only one patient in 
our cohort was identified with a monogenic disease involving B cell dysfunction. That is, a 
novel mutation in IKZF1, encoding the transcription factor IKAROS, playing a role in B cell 
development. No mutations were identified in PRKCD, previously associated with monogenic 
lupus10. Thus, whilst SLE is often considered as a B cell driven disease, the majority of 
Mendelian forms observed in our cSLE relates to mutations in innate immunity related genes. 
 
In cSLE patients compared to controls, we observed an increased frequency of monoallelic 
variants in KLC genes described to cause lupus as an autosomal recessive trait in both type I 
interferonopathy and complement related genes. In this group the sex ratio was 4:3, and the 
onset of disease was very early, possibly suggesting a significant impact of the observed 
heterozygous variants on disease induction. Among these variants, a TREX1 mutation has 
already been reported in AGS, a recognized type I interferonopathy associated with an 
increased risk of SLE8. Günther et al. also described an increase of rare heterozygous 
variants in components of the RNase H2 complex in lupus7. Using our filtering strategy, one 
patient was detected with a heterozygous RNASEH2C predicted pathogenic substitution. Of 
note, the SKAT-O test also highlighted a higher rare-disease burden for this gene in the 
lupus population. We recorded an ACP5 missense variant in one patient. Biallelic mutations 
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in ACP5 are a cause of Mendelian lupus, and an increase of predicted pathogenic 
heterozygous variants in this gene has been reported in an SLE cohort24. The patient 
carrying the novel variant in C3 displayed features of lupus nephritis and haemolytic uremic 
syndrome (HUS), with C3 deficiency a known cause of HUS. We also noticed markedly 
decreased levels of C3 in this patient, strongly arguing for a genetic contribution of the 
variant to the phenotype. Overall, these observations support the possibility that genes 
known as directly causal of classical Mendelian lupus may play an important role in driving 
susceptibility to complex disease. Indeed, a recent report using whole genome sequencing 
identified an enrichment of heterozygous variants in genes related to monogenic lupus in an 
SLE cohort25. In addition, de novo monoallelic mutations have been described in KLC genes, 
including PRKCD, in cSLE patients, further supporting the contention of a genetic driven 
threshold for the occurrence of autoimmunity26. 
 
We identified 15 patients with heterozygous, putative mutations in PLC genes. The frequency 
of these rare, predicted damaging variants was also significantly increased in cSLE patients 
compared to the controls, suggesting that they might represent novel SLE predisposing 
alleles. Furthermore, some filtered variants co-segregated in a single individual. For 
example, Pt8 carried a LYN substitution associated with the novel IKZF1 mutation discussed 
above, whilst Pt10 was identified with a novel, predicted damaging variant in each of ACP5 
and RASGRP3. It seems plausible that a lupus phenotype might be driven by pathogenic 
variants in two or more genes. Consistent with this hypothesis, we demonstrated an 
accumulation of rare and predicted damaging variants in individual cSLE patients compared 
to controls. It is important to emphasize that the number of rare variants per se did not vary 
between these populations; rather, it was the combination of variant frequency and 
pathogenicity score which distinguished the two groups in terms of monoallelic variant 
burden, with an odds ratio between patients and controls of from 11.1 to 17.1, and from 2.83 
to 4.4 in the KLC and PLC gene sets respectively. Of note, a recent study in patients with 
C1R deficiency also suggested that common SLE-associated variants may influence the 
severity of an otherwise monogenic disease state27.  
 
Using our strategy, focusing on exons and polymorphisms with predicted functional 
consequences, we identified putative disease causing variants in the coding regions of genes 
already detected in GWAS studies. As examples, we recorded two unrelated patients 
carrying the same variant in PDHX, and a novel PTPN22 variant was observed in one 
patient. Rare variants may contribute to the burden of the disease, with their accumulation 
influencing age at onset and clinical spectrum. Rare variants in two genes identified in 
GWAS studies, BLK and BANK1, were also recently identified in lupus patients with 
functional impact on B cell biology28. In our study, the bioinformatic filter we used was more 
stringent, and filtered out some of these variants in these genes. In addition, we may have 
missed functionally relevant regulatory variants located in non-coding regions of the genome 
that were not captured by the panel. Thus, given the stringency of the bioinformatic algorithm 
that we employed, our study probably underestimates the genetic contribution of the genes 
selected here. Furthermore, parental DNA was not systematically available in all patients, 
preventing us from detecting de novo mutations that might have otherwise been identified by 
trio analyses25. Finally, by limiting our analysis to a 147 gene panel we omit several other 
genes that may contribute to a Mendelian susceptibility to lupus. Functional studies were 
only performed when material was available, and to robustly address the contribution of 
interesting variants, their introduction into cellular and/or animal models may prove helpful.  
 
Studying extreme phenotypes of complex disease represents a powerful strategy to simplify 
and understand human pathology. Our analysis highlights the heterogeneity of the genetic 
basis of cSLE, with 25% of the cSLE population carrying at least one rare and predicted 
damaging variant. Numerous clinical trials have failed to demonstrate a positive effect of a 
variety of medications in SLE, and current clinical and laboratory criteria are clearly not 
sufficient to detect specific factors determining treatment outcome. Explicitly considering 
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rare, high penetrant gene variants might identify patient subsets with distinct therapeutic 
responses, thereby enabling personalized treatments according to genetic background and 
molecular taxonomy28.  
 
Research in Context 
 
Evidence before this study 
 
Familial aggregation, and higher concordance rates between monozygotic (20 – 40%) relative to 
dizygotic twins and other full siblings (2 – 5%), suggest a major hereditary component to the 
pathogenesis of systemic lupus erythematosus (SLE). Whilst genome-wide association studies 
(GWAS) have identified more than 90 loci as robustly associated with the lupus phenotype, it is an 
overlooked fact that Mendelian forms of lupus have been described in the context of almost 30 
discrete genotypes in humans, referred to here as the Mendeliome, and more than 60 single gene 
defects in mice. At present, the significance of these observations for the understanding of lupus 
biology remains unclear. 
 
Added value of this study 
 
To address the issue of the genetic contribution to lupus in children, we performed an analysis of 147 
genes at depth, selected on the basis of their involvement in lupus pathogenesis, in 117 unrelated 
probands with SLE demonstrating onset before the age of 16 years. Within the Mendeliome, we 
observed mutant genotypes to be present in 7% of probands. Furthermore, heterozygous, predicted 
pathogenic variants in genes previously implicated in lupus causation were significantly enriched in the 
SLE cohort compared to controls. Of further interest, our study supports the concept of oligogenicity in 
SLE genetic susceptibility, with an accumulation of rare, predicted pathogenic variants in different 
genes in patients. 
 
Implication of the available evidence 
 
Numerous clinical trials in SLE have failed to demonstrate a positive effect of a variety of study drugs, 
and current clinical and laboratory criteria are clearly not sufficient to detect specific factors 
determining treatment outcome. Our results are consistent with an underlying heterogeneity of the 
lupus phenotype, with dysfunction of innate immunity playing an important role. Our data suggest that 
an exploration of genetic burden in single individuals may be informative in tailoring future 




YJC acknowledges the European Research Council (GA 309449; and 786142 - E-T1IFNs), ERA-NET 
Neuron (MR/M501803/1) and a state subsidy managed by the National Research Agency (France) 
under the "Investments for the Future" program bearing the reference ANR-10-IAHU-01. AB 
acknowledges the French ANR program 14-CE14-0026 LUMUGENE and the “Jeune Chercheur” 
support from Hospices Civils de Lyon. TAB acknowledges the National Institute for Health Research 
(NIHR) (NIHR Transitional Research Fellowship, Dr Tracy Briggs, TRF-2016-09-002) and the Medical 
Research Foundation. TAB and INB acknowledge funding from the NIHR Manchester Biomedical 
Research Centre. The views expressed are those of the author(s) and not necessarily those of the 
NHS, the NIHR or the Department of Health. JME is funded by a postdoctoral research fellowship from 
the Health Education England Genomics Education Programme (HEE GEP). The views expressed in 
this publication are those of the authors and not necessarily those of the HEE GEP. MWB 
acknowledges the UK JSLE Cohort Study is supported by Lupus UK (#LUPUS UK: JXR10500, 
JXR12309), the UK ‘Experimental Arthritis Treatment Centre for Children’ supported by Arthritis 
Research UK (ARUK #20621), the Alder Hey Charity, University of Liverpool, Alder Hey Children’s 
NHS Foundation Trust and the National Institute of Health Research (NIHR) Alder Hey Clinical 
Research Facility. The authors would like to acknowledge all patients and their families for 
participating in the UK JSLE and the GENIAL cohort studies, and are grateful to all the support given 
by the local principle investigators and entire multi-disciplinary teams within each of the paediatric 
centres as part of the UK JSLE Study Group (https://www.liverpool.ac.uk/translational-
 12 




1.  Criswell LA. The genetic contribution to systemic lupus erythematosus. Bull NYU 
Hosp Jt Dis 2008;66(3):176–83.  
2.  Bentham J, Morris DL, Graham DSC, et al. Genetic association analyses implicate 
aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic 
lupus erythematosus. Nat Genet 2015;47(12):1457–64.  
3.  Kono DH, Theofilopoulos AN. Genetics of SLE in mice. Springer Semin 
Immunopathol 2006;28(2):83–96.  
4.  Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex 
diseases. Nature 2009;461(7265):747–53.  
5.  Al-Mayouf SM, Sunker A, Abdwani R, et al. Loss-of-function variant in DNASE1L3 
causes a familial form of systemic lupus erythematosus. Nat Genet 2011;43(12):1186–8.  
6.  Sisirak V, Sally B, D’Agati V, et al. Digestion of Chromatin in Apoptotic Cell 
Microparticles Prevents Autoimmunity. Cell 2016;166(1):88–101.  
7.  Günther C, Kind B, Reijns MAM, et al. Defective removal of ribonucleotides from DNA 
promotes systemic autoimmunity. J Clin Invest 2015;125(1):413–24.  
8.  Lee-Kirsch MA, Gong M, Chowdhury D, et al. Mutations in the gene encoding the 3′-5′ 
DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 
2007;39(9):1065.  
9.  Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell 
hyperactivity. Nat Immunol 2001;2(9):764.  
10.  Belot A, Kasher PR, Trotter EW, et al. Protein kinase cδ deficiency causes mendelian 
systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis 
Rheum 2013;65(8):2161–71.  
11.  Hoshino A, Okada S, Yoshida K, et al. Abnormal hematopoiesis and autoimmunity in 
human subjects with germline IKZF1 mutations. J Allergy Clin Immunol 2017;140(1):223–31.  
12.  Jordan DM, Do R. Using Full Genomic Information to Predict Disease: Breaking 
Down the Barriers Between Complex and Mendelian Diseases. Annu Rev Genomics Hum 
Genet 2018;19:289–301.  
13.  Brodin P, Davis MM. Human immune system variation. Nat Rev Immunol 
2017;17(1):21–9.  
14.  Watson L, Leone V, Pilkington C, et al. Disease activity, severity, and damage in the 
UK juvenile-onset systemic lupus erythematosus cohort. Arthritis Rheum 2012;64(7):2356–
65.  
15.  López-Lera A, Torres-Canizales JM, Garrido S, Morales A, López-Trascasa M. 
Rothmund-Thomson syndrome and glomerulonephritis in a homozygous C1q-deficient 
patient due to a Gly164Ser C1qC mutation. J Invest Dermatol 2014;134(4):1152–4.  
16.  Johnson CA, Densen P, Wetsel RA, Cole FS, Goeken NE, Colten HR. Molecular 
heterogeneity of C2 deficiency. N Engl J Med 1992;326(13):871–4.  
17.  Ozçakar ZB, Foster J, Diaz-Horta O, et al. DNASE1L3 mutations in 
hypocomplementemic urticarial vasculitis syndrome. Arthritis Rheum 2013;65(8):2183–9.  
18.  Han J-W, Zheng H-F, Cui Y, et al. Genome-wide association study in a Chinese Han 
population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 
2009;41(11):1234–7.  
19.  Kuehn HS, Boisson B, Cunningham-Rundles C, et al. Loss of B Cells in Patients with 
Heterozygous Mutations in IKAROS. N Engl J Med 2016;374(11):1032–43.  
20.  Crow YJ, Chase DS, Lowenstein Schmidt J, et al. Characterization of human disease 
phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, 
SAMHD1, ADAR, and IFIH1. Am J Med Genet A 2015;167A(2):296–312.  
21.  Nozal P, Garrido S, Martínez-Ara J, et al. Case report: lupus nephritis with 
autoantibodies to complement alternative pathway proteins and C3 gene mutation. BMC 
Nephrol 2015;16:40.  
 13 
22.  Banchereau R, Hong S, Cantarel B, et al. Personalized Immunomonitoring Uncovers 
Molecular Networks that Stratify Lupus Patients. Cell 2016;165(6):1548–50.  
23.  An J, Briggs TA, Dumax-Vorzet A, et al. Tartrate-Resistant Acid Phosphatase 
Deficiency in the Predisposition to Systemic Lupus Erythematosus. Arthritis Rheumatol 
Hoboken NJ 2017;69(1):131–42.  
24.  Almlöf JC, Nystedt S, Leonard D, et al. Whole-genome sequencing identifies complex 
contributions to genetic risk by variants in genes causing monogenic systemic lupus 
erythematosus. Hum Genet 2019;138(2):141–50.  
25.  Pullabhatla V, Roberts AL, Lewis MJ, et al. De novo mutations implicate novel genes 
in systemic lupus erythematosus. Hum Mol Genet 2018;27(3):421–9.  
26.  Demirkaya E, Zhou Q, Smith CK, et al. Brief Report: Deficiency of Complement 1r 
Subcomponent in Early-Onset Systemic Lupus Erythematosus: The Role of Disease-
Modifying Alleles in a Monogenic Disease. Arthritis Rheumatol Hoboken NJ 
2017;69(9):1832–9.  
27.  Jiang SH, Athanasopoulos V, Ellyard JI, et al. Functional rare and low frequency 
variants in BLK and BANK1 contribute to human lupus. Nat Commun 2019;10(1):2201.  
28.  Barturen G, Beretta L, Cervera R, Van Vollenhoven R, Alarcón-Riquelme ME. Moving 
towards a molecular taxonomy of autoimmune rheumatic diseases. Nat Rev Rheumatol 
2018;14(3):180.  
29.  Carbonella A, Mancano G, Gremese E, et al. An autosomal recessive DNASE1L3-
related autoimmune disease with unusual clinical presentation mimicking systemic lupus 




AB and YJC conceived the study, planned, designed and interpreted experiments and wrote 
the initial draft. GIR performed PCR sequencing and participated in variant analysis with TL. 
EG, GM performed SKAT-O analyses. QR and RB performed the initial filtering of variants 
and the first analyses on the dataset. JOS, PARF, CB, TS, TL, TB, GIR analysed the panel 
data, 1000g and FREX data. Complement dosage was performed by MNS. Autoantibody 
screening was performed by NF. Structural 3D structures were provided by NT and CG. 
Biobanking and processing of samples were undertaken by EC and IR. SL and AH 
generated EMSA for Ikaros variant. Functional immunological and transcriptome studies 
were performed by SOO, MM, MT, SV, and KK. ES, CF, BR, RC, PR, BK,  JCL, SD, PA, HR, 
BBM and MB provided clinical samples and critically reviewed patient data. GENIAL 
Investigators, UK JSLE Study Group provided additional samples. The FREX Consortium 
and samples from Professor G Evans, Manchester Centre for Genomic Medicine with 
sequencing funded by the BRC provided control data. All authors reviewed the manuscript 
and agreed to its submission. 
 14 
Figure 1. Demographic characteristics of the cSLE cohort and bioinformatic analysis 
strategy. Ethnicity (A), age and sex (B) of the 117 probands in the cSLE cohort. (C) 
Schematic of the bioinformatic pipeline used to detect rare predicted damaging variants, 
leading to the definition of three categories of patient: 8 patients with monogenic SLE; 8 
patients carrying monoallelic variants in autosomal recessive known lupus causing (KLC) 
genes; 16 additional patients with filtered variants in potentially lupus causing (PLC) genes. 
Total and individual variant numbers are presented before and after the application of filters 
of rarity and pathogenicity in the SLE (D) and 1000g (E) cohorts. Note that three patients in 
the KLC groups carried additional rare and predicted damaging variants in PLC genes, as 
indicated in brackets. 
 
Figure 2. Complement deficiencies in cSLE. Pedigrees of families with mutations in C1q 
(A), C2 (D),(black shading represents affected cSLE status), with identified mutations shown 
below each pedigree. (B) Structure of C1q globular domain with C1qA (red), C1qB (green) 
and C1qC (blue), calcium ion (yellow) and representation of the Gly164 residue (magenta). 
This amino acid is highly conserved across the C1q family. The glycine at position 164 is 
located near the junction between the collagen-like stem (red, green and blue circles) with 
the globular domain. The glycine is tightly packed into the structure, and any substitution is 
predicted to destabilize the assembly of the three chains. (C) ELISA quantification of 
complement components in sera from patients with C1Q and (E) C2 deficiency.  
 
Figure 3: Other genetic defects in the Mendeliome. (A) Family pedigree of Pt 7. (B) 
Representation of the DNASE1L3 protein showing the T97Ifs*2 substitution and the deletion 
identified in Pt7 (red) and parents with linear representation of DNASE1L3 and the only other 
mutation so-far reported within the coding region (black). (C) Family pedigree of Pt 8 with (D) 
position of the D120V mutation (red) in the IKAROS zinc finger domain required for DNA-
binding, and previously reported mutations (black). NIH3T3 cells were transfected with HA-
tagged WT or D120V mutant expression vectors labelled with anti-HA antibody and an Alexa 
488-conjugated (green) secondary antibody. Cells were visualized using confocal 
microscopy. Mutant D120V was analysed for DNA binding with the use of an electrophoretic 
mobilityshift assay (EMSA), and compared to the already reported defective variant R162Q 
(E) Heat map of regulated genes by RNA-Seq analyses in Granta cells with transfection of 
inducible WT-IKZF1 or D120V-IKZF1 (left panel without induction, right panel following 
induction). (F) Transcriptomic activity of WT and D120V variant. 
 
Figure 4. Rare and predicted damaging variants in cSLE and phenotypes. (A) 
Heterozygous variant mean of SNPs in known lupus causing (KLC) genes previously 
associated with lupus causation as an autosomal recessive trait, in cSLE probands 
compared to controls in 1000g and FREX database. (B) Heterozygous variant mean of SNPs 
in putative lupus causing (PLC) genes in cSLE probands compared to controls in 1000g and 
FREX database. (C) Odds ratio for the mutational load in KLC (A) and PLC (B) genes of 
SNPs under the different filtering conditions of the lupus patients compared to 1000g or 
FREX cohorts (E) Number of KLC and PLC genes per individual in which a rare, predicted 
damaging variant was identified in cSLE probands and controls. (F) Representation of genes 
with either filtered variants (inner white circle) or without filtered variants (outer grey circle). 
Chromosome localization and number of filtered variants (innermost coloured dots) are 
indicated. Variants were divided into three categories: causal for monogenic disease (red), 
heterozygous in KLC genes previously associated with lupus causation as an autosomal 
recessive trait (orange), or PLC (blue) genes. Putative di- or tri-genic associations of variants 
in a single proband are signified by connecting lines.  
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Supplementary figure S1. Coding region filter. The boxes outline what we refer to as the 
coding region i.e. exons and canonical splice site nucleotides. 
 
Supplementary figure S2. Population comparability 
Principal component analysis of the distribution of frequent variants in the cSLE panel and 
1000g populations showing three subgroups of populations within the two populations. 
 
Supplementary figure S3. Phenotype according to genotype. Spider plots of the 
frequency of clinical features seen in: A) cSLE patients with Mendelian disease (n = 8); (B) 
probands carrying heterozygous variants in autosomal recessive KLC genes (n = 8); (C) 
probands with variants in PLC genes (n = 16); and (D) probands with no identified filtered 
variants (n = 85). Sex ratios and age at diagnosis are provided for each plot. Sex ratio, 
male:female; age, median age at onset in years; SD: standard deviation. 
 
16 
Table 1: Patients carrying filtered variant in know
n lupus causing (KLC
) genes (bold) (w
ith additional filtered variants, underlined), defining 
M
endelian SLE (Pt 1 to 8) or carrying heterozygous rare, predicted dam
aging variants in genes know
n to cause autosom































































































































































































































































































































































































































































































































 Table 2: R
are, predicted dam




















































































































































































































































































































Here is provided supplemental information by the authors. 
 
1. Materials and methods………………………………...……………….p2 - 4 
2. Supplementary table S1………………………………………..………p5 - 10 
3. Supplementary table S2……………………………………………..…p11 - 55 
4. Supplementary table S3……………………………………………..…p57-60 
5. Supplementary table S4………………………………………………..p61 
6. Supplementary table S5………………………………………………..p62 
7. Supplementary table S6………………………………………………..p63 
8. Supplementary table S7………………………………………………..p64 - 65 
 
Supplemental Appendix Click here to view linked References
 2 




One hundred and seventeen unrelated probands were identified from the UK Juvenile-onset 
SLE (JSLE) Cohort Study (Watson et al., 2012) and French SLE GENIAL (Clinicaltrials.gov, 
NCT01992666) cohorts. All patients fulfilled American College of Rheumatology (ACR) 
criteria for lupus and were diagnosed before the age of 16 years. Linked clinical data were 
recorded in the two respective nationwide databases. The study was approved by the Sud-
Est III ethics committee (#2013-011B), French Data Protection Authority (CNIL, #DR-2013-
354), French Advisory Committee on Healthcare Research Data Processing (CCTIRS, 
#2013.223), the National Research Ethics Service North West, Liverpool East, UK (reference 
06/Q1502/77) and the Leeds (East) Research Ethics Committee, UK (reference number 
10/H1307/132). In agreement with the International Genome Sample resource (IGSR; 
http://www.internationalgenome.org) criteria for the classification of ethnicity, the combined 
cohort of pediatric onset SLE examined here was made up of the following ethnicities: 




Control data were derived from the 1000 Genomes Project (1000g)16. The healthy control 
cohort comprised 791 unrelated individuals demonstrating a similar ethnic distribution to the 
cSLE cohort (50% European, 33% African; 16% South Asian), built by random sampling 
among the 1000g sample set. Two additional control populations were ascertained through 
the FREX consortium, a French-specific database of 574 individuals of French ancestry and 
a UK control panel: 74 adults from the north west of England,  
The FREX consortium exome database is a French-specific database containing the exome 
data of a reference control panel of individuals of French ancestry (n = 574). (Website: 
http://lysine.univ-brest.fr/FrExAC/). The FREX cohort is a federative project that aims at 
building such a database and giving access to the scientific community exome data that can 
serve as controls in association studies. A total of 574 healthy individuals sampled in 6 
French regions have been sequenced using the Agilent V5+UTR exome capture kit and 
genotyped on Illumina Core Exome SNP-chip.  
A cohort of 74 adults from the north west of England and were screened using an identical 
pipeline, arising from the CTD project (LEAP), led by Pr. Ian Bruce and funded by the BRC. 
The patients were sequenced and analysed using exactly the same targeted exon panel, 




We designed a next-generation sequencing panel selecting genes after a systematic search 
of Pubmed to January 2013, considering combinations of the following terms: “Mouse 




Targeted enrichment and sequencing of our panel of 146 genes was undertaken using 200 
ng of DNA extracted from peripheral blood. Enrichment was performed with the Sure Select 
Custom Target Enrichment Kit (Agilent Technologies, Santa Clara, CA, USA) for the Illumina 
HiSeq system following the manufacturer's protocols. Samples were paired-end sequenced 
on on a Illumina HiSeq 2500 sequencer (Illumina Inc, San Diego, CA, USA). More than 96% 
of targeted bases were sequenced to a read depth of greater than 30. Rare variants, defined 
here as a frequency on the Exome Aggregation Consortium (ExAC, 0.2) database of <0.1% 
for SNPs and <1% for indels, were selected for further analysis. Studied variants were 
confirmed by Sanger sequencing (primers available on request).  
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Variant discovery and annotation  
 
Variant discovery analysis was performed following Genome Analysis Toolkit (GATK) best 
practice guidelines(Van der Auwera et al., 2013). Raw data (fastq files) were preliminarily 
split according to the number of reads for optimal base quality score recalibration. Reads 
were then aligned to the reference genome assembly GRCh37 with BWA-MEM (version 
0.7.12), using appropriate read group annotations. Duplicate reads were marked using 
Picard (version 1.140). We utilized GATK (version 3.4) to realign reads around indels with 
the 1000 Genomes Project (1000g)(The 1000 Genomes Project Consortium, 2010) phase 1 
indel call reference and 1000g gold standard indel sets. Same procedure was performed for 
the Frex consortium database and UK control population for SNPs only. Base quality scores 
were recalibrated using the two aforementioned indel sets and the dbSNP138 release. 
Analysis-ready reads belonging to the same sample, but with different lane number, were 
then merged. To increase the quality of the results, an additional round of duplicate read 
marking and realignment was performed on merged files. 
 
Single nucleotide variants (SNV) and indels were called simultaneously on each sample via 
local reassembly using the GATK HaplotypeCaller tool to produce an intermediate variant 
set. Joint genotyping was then performed on the files from all 117 individuals. Variants were 
filtered using variant quality score recalibration, and low quality (GQ < 20) reads removed. 
Copy number variants (CNVs) were identified according to a read-depth approach. 
ExomeDepth v1.1.6(Plagnol et al., 2012) was applied to non-duplicate sequencing reads 
aligned to GRCh37. CNV calling was performed utilizing other samples generated through 
the same sequencing run and bioinformatics strategy. Variants were annotated using 
Ensembl Variant Effect Predictor (VEP) 83 and Annovar(Wang et al., 2010). We considered 
SIFT(Ng and Henikoff, 2003), Polyphen-2(Adzhubei et al., 2013) and Combined Annotation 
Dependent Depletion (CADD) v1.3(Kircher et al., 2014) scores for computational predictions 





Variants extracted from the raw data in VCF files were filtered using the following steps: 
segregation into two subsets, insertions/deletions (indels) and SNVs; filtering of indels and 
SNVs according to their population frequencies within the ExAC dataset, where we employed 
1% and 0.1% respectively in the case of putative biallelic mutations, or 0.01% and 0.001% in 
the case of heterozygous variants, as our thresholds (threshold (heterozygous) = threshold 
(homozygous)2 i.e. 10-4 for indels and 10-6 for SNVs). Finally, we selected indels with a 
CADD score higher than 15, and SNVs according to the formula: CADD score ≥ 15 AND sift 
score ≤ 0.05 AND Polyphen 2 score ≥ 0.9. A cartoon of the characterization of different 
sequence variants is given in Figure S1 in the Supplementary Appendix. For the UK control 
population, CADD>15 only was considered for the analysis. 
 
cDNA cloning, expression and DNA binding studies 
 
cDNA coding for IKZF1 was a kind gift from A. Liston (Leuven). cDNA was PCR amplified 
and cloned in a p3xFlagCMV vector (Sigma-Aldrich, France) that enables expression of 
IKAROS N-terminal Flag tagged protein. Directed mutagenesis was performed on this 
construct to obtain the IKZF1 c.A359T (p.D120V) variant. For IKAROS nuclear staining 
experiments, Flag-tagged human WT or D120V Ikaros plasmids were transfected into 
NIH3T3 cells using JetPEI transfection reagent (PolyPlus Transfection, France). Forty eight 
hours after transfection, cells were stained using primary mouse anti-Flag antibody (Sigma-
Aldrich, France) and secondary anti-mouse AF488 antibody (Jackson ImmunoResearch, 
UK). Nuclei were stained using DAPI (Thermo Fisher Scientific, France). Images were 
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collected on a LSM 710 confocal microscope (Zeiss, Germany) with a 63x immersion 
objective. 
 
C1q Structure analysis 
 
Structural analysis was performed using MacPymol 1.3 software and C1q structure PDB 
1PK6(Gaboriaud et al., 2003). 
 
IZKF1 functional data  
 
Granta cell sample preparation 
Granta cells were transduced with inducible lenti-vector pInducer21 (ORF-EG) (Addgene) 
expressing either wt-IKZF1 or D120V-IKZF1. Four days following transduction, GFP positive 
cells were sorted using a FACSAria Cell Sorter (Becton-Dickinson, San Jose, USA). For the 
IKZF1 transcriptomic study, cells were plated at 1.106 cells/ml in 6 well plate and treated or 
not with doxycycline at 0.5µg/ml during 6 hours. Cells were then pelleted and total RNA 
extracted using Direct-Zol RNA MicroPrep w/ Zymp-Spin Columns and following 
manufacturer’s instructions (Ozyme). Total RNA was quantified using Quantifluor RNA 
system (Promega). 
 
Library preparation and RNASeq and analysis: Libraries were generated from 1µg of total 
RNA from doxycycline induced or non induced Granta cell lines. Libraries were generated 
with SENSE™ mRNA-Seq Library Prep Kit V2 (Lexogen) following the manufacturer’s 
instructions. Tagged library quality was checked on D1000 screen tape and analysed on 
Tape station 4200 (Agilent). Libraries sequencing was performed by the GenomEast 
platform, a member of the “France Génomique” consortium (ANR-10-INBS- 0009). Cutadapt 
1.10 (--adapter AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC --quality-cutoff 20,20 –
anywhere "Af100g" --minimum-length 40) was used for read preprocessing: adapter, poly-A 
tail and low-quality (Phred quality score below 20) base trimming, removal of reads shorter 
than 40 bp after trimming. Reads mapping to rRNA sequences were also discarded. Reads 
were then mapped onto the hg38 assembly of Homo sapiens genome using STAR (7) 
version 2.5.3a (--twopassMode Basic). Gene expression was quantified using htseq-count 
(8) release 0.6.1p1 (--mode union --minaqual 10) and gene annotations from Ensembl 
release 94. Statistical analysis was performed using R and DESeq2 1.16.1 Bioconductor 
library (9). Genes were selected as differentially expressed using the following thresholds: 




Fisher's exact test was used to compare the frequencies of variants in the control and cSLE 
cohorts. Data normality was assessed using a Shapiro-Wilk test and quantile-quantile plots. 
The mean of SNPs per individual was compared between control and cSLE cohorts using a 
Mann-Whitney U test (Wilcoxon rank-sum test). P-values were adjusted using the Bonferroni 
correction where appropriate. Odd ratios were calculated using the standard formula, with 
S1/2 the number of variants that passed a filter and F1/2 those which failed for the two 
groups compared (OR = S1*F2 / F1*S2). 
SKAT-O analysis was performed rare variants with a MAF of 1% or 0.1% within the selected 
genes to analyse the genes differentially distributed in the lupus patients compared to 





Supplemental table S1: Genotypes associated with putative monogenic SLE, known 
lupus-causing genes (KLC, also referred as Mendeliome) (n = 28)(defined as of 
2013) 
 
Gene Pathogenesis Kegg pathways References 
ACP5  Interferon 
signaling 
ko00740   Riboflavin 
metabolism 
ko01100   Metabolic pathways 
ko04142   Lysosome 
ko04380   Osteoclast 
differentiation 
ko05323   Rheumatoid arthritis 
 
(An et al., 2016; 
Briggs et al., 2011; 
Lausch et al., 2011) 
C1Q(A,B,C)  Complement ko04610   Complement and 
coagulation 
cascades 
ko05020   Prion diseases 
ko05133   Pertussis 
ko05142   Chagas disease 
(American 
trypanosomiasis) 
ko05150   Staphylococcus 
aureus infection 
ko05322   Systemic lupus 
erythematosus 
 
(Botto et al., 1998; 
Martens et al., 2009) 
C1R  Complement ko04145   Phagosome 
ko04610   Complement and 
coagulation 
cascades 
ko05133   Pertussis 
ko05150   Staphylococcus 
aureus infection 
ko05322   Systemic lupus 
erythematosus 
 
(Lee et al., 1978) 
C1S  Complement ko04610   Complement and 
coagulation 
cascades 
ko05133   Pertussis 
ko05150   Staphylococcus 
aureus infection 
ko05322   Systemic lupus 
erythematosus 
 
(Amano et al., 2008; 
Dragon-Durey et al., 
2001; Lee et al., 
1978) 
C2  Complement   
map00140   Steroid hormone 
biosynthesis 
 
(Stern et al., 1976) 
 
C3  Complement hsa04145   Phagosome 
hsa04610   Complement and 
coagulation 
cascades 
hsa05133   Pertussis 
hsa05134   Legionellosis 
hsa05140   Leishmaniasis 
(Tsukamoto et al., 
2005) 
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hsa05142   Chagas disease 
(American 
trypanosomiasis) 
hsa05150   Staphylococcus 
aureus infection 
hsa05152   Tuberculosis 




hsa05168   Herpes simplex 
infection 
hsa05203   Viral 
carcinogenesis 
hsa05322   Systemic lupus 
erythematosus 
 
C4A  Complement hsa04610   Complement and 
coagulation 
cascades 
hsa05133   Pertussis 
hsa05150   Staphylococcus 
aureus infection 
hsa05322   Systemic lupus 
erythematosus 
 
(Chen et al., 2000; 
Fischer et al., 1998; 
Paul et al., 2002) 
C4B  Complement hsa04610   Complement and 
coagulation 
cascades 
hsa05133   Pertussis 
 
 
(Hartung et al., 1992; 
Yang et al., 2007) 
C5 Complement ko04610   Complement and 
coagulation 
cascades 
ko05020   Prion diseases 
ko05133   Pertussis 
ko05150   Staphylococcus 
aureus infection 
ko05168   Herpes simplex 
infection 




(Asghar et al., 1991) 
C6 Complement ko04610   Complement and 
coagulation 
cascades 
ko05020   Prion diseases 




(Trapp et al., 1987) 
C7 Complement ko04610   Complement and 
coagulation 
cascades 
ko05020   Prion diseases 
ko05322   Systemic lupus 
erythematosus 
 
(Segurado et al., 
1992) 
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C8A Complement ko04610   Complement and 
coagulation 
cascades 
ko05020   Prion diseases 
ko05146   Amoebiasis 




C8B Complement ko04610   Complement and 
coagulation 
cascades 
ko05020   Prion diseases 
ko05146   Amoebiasis 




C9 Complement ko04610   Complement and 
coagulation 
cascades 
ko05020   Prion diseases 
ko05146   Amoebiasis 
ko05322   Systemic lupus 
erythematosus 
 
(Kawai et al., 1989) 
DNASE1  Interferon 
signaling 
 (Bodaño et al., 2006; 
Napirei et al., 2000; 
Yasutomo et al., 
2001) 
DNASE1L3  Interferon 
signaling 
 (Al-Mayouf et al., 
2011; Ozçakar et al., 
2013) 
FAS  Central tolerance ko01524   Platinum drug 
resistance 
ko04010   MAPK signaling 
pathway 
ko04060   Cytokine-cytokine 
receptor interaction 
ko04115   p53 signaling 
pathway 
ko04210   Apoptosis 
ko04217   Necroptosis 
ko04650   Natural killer cell 
mediated cytotoxicity 
ko04668   TNF signaling 
pathway 
ko04932   Non-alcoholic fatty 
liver disease 
(NAFLD) 
ko04940   Type I diabetes 
mellitus 
ko05010   Alzheimer disease 
ko05142   Chagas disease 
(American 
trypanosomiasis) 
ko05143   African 
(Adachi et al., 1993; 
Watson et al., 1992) 
 8 
trypanosomiasis 
ko05161   Hepatitis B 
ko05162   Measles 
ko05163   Human 
cytomegalovirus 
infection 
ko05164   Influenza A 
ko05165   Human 
papillomavirus 
infection 
ko05167   Kaposi sarcoma-
associated 
herpesvirus infection 
ko05168   Herpes simplex 
infection 
ko05200   Pathways in cancer 
ko05205   Proteoglycans in 
cancer 
ko05320   Autoimmune thyroid 
disease 
ko05330   Allograft rejection 
ko05332   Graft-versus-host 
disease 
 
FASLG  Central tolerance ko01524   Platinum drug 
resistance 
ko04010   MAPK signaling 
pathway 
ko04014   Ras signaling 
pathway 
ko04060   Cytokine-cytokine 
receptor interaction 
ko04068   FoxO signaling 
pathway 
ko04151   PI3K-Akt signaling 
pathway 
ko04210   Apoptosis 
ko04217   Necroptosis 
ko04650   Natural killer cell 
mediated cytotoxicity 
ko04722   Neurotrophin 
signaling pathway 
ko04932   Non-alcoholic fatty 
liver disease 
(NAFLD) 
ko04940   Type I diabetes 
mellitus 
ko05142   Chagas disease 
(American 
trypanosomiasis) 
ko05143   African 
trypanosomiasis 
(Lynch et al., 1994; 
Takahashi et al., 
1994) 
 9 
ko05161   Hepatitis B 
ko05162   Measles 
ko05163   Human 
cytomegalovirus 
infection 
ko05164   Influenza A 
ko05165   Human 
papillomavirus 
infection 
ko05168   Herpes simplex 
infection 
ko05200   Pathways in cancer 
ko05205   Proteoglycans in 
cancer 
ko05320   Autoimmune thyroid 
disease 
ko05330   Allograft rejection 
ko05332   Graft-versus-host 
disease 
 
IFIH1  Interferon 
signaling 
ko04622   RIG-I-like receptor 
signaling pathway 
ko05161   Hepatitis B 
ko05162   Measles 
ko05164   Influenza A 
ko05168   Herpes simplex 
infection 
  
(Robinson et al., 
2011) 
IKZF1  Central tolerance  (Hoshino et al., 2017) 
MFGE8  Efferocytosis  (Hanayama et al., 
2004; Hu et al., 2009; 
Yamaguchi et al., 
2008) 
PRKCD  Central tolerance ko04062   Chemokine signaling 
pathway 
ko04140   Autophagy - animal 
ko04270   Vascular smooth 
muscle contraction 
ko04621   NOD-like receptor 
signaling pathway 
ko04625   C-type lectin 
receptor signaling 
pathway 
ko04666   Fc gamma R-
mediated 
phagocytosis 
ko04722   Neurotrophin 
signaling pathway 
ko04750   Inflammatory 
mediator regulation 
of TRP channels 
ko04912   GnRH signaling 
pathway 
(Belot et al., 2013; 
Mecklenbräuker et 
al., 2002; Miyamoto 
et al., 2002) 
 10 
ko04915   Estrogen signaling 
pathway 
ko04930   Type II diabetes 
mellitus 
ko04931   Insulin resistance 
ko04933   AGE-RAGE 









ko03030   DNA replication 
 
(Ramantani et al., 
2010) 
TREX1  Interferon 
signaling 
ko04623   Cytosolic DNA-
sensing pathway 
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Supplemental Table S7: SKAT-O test for genes filtered in by the algorithm. Frequency 
of 0.1% and 1% in Exac were tested. 
 
gene chr pos ExAC_Fq pSKAT-O 
ACP5 19 11687884 0,.10% 0,.1166 
ACP5 19 11687884 1% 0,.1166 
C1QC 1 22973915 0,.10% 0,.0057 
C1QC 1 22973915 1% 0,.0057 
C2 6 31896638 0,.10% 0,.6901 
C2 6 31896638 1% 0,.6901 
C3 19 6680256 0,.10% 0,.0667 
C3 19 6680256 1% 0,.0607 
C8B 1 57409469 0,.10% 1,.0000 
C8B 1 57409469 1% 1,.0000 
C9 5 39288980 0,.10% 0,.1171 
C9 5 39288980 1% 0,.2263 
CBLB 3 105378034 0,.10% 0,.5063 
CBLB 3 105378034 1% 0,.5063 
CD19 16 28948667 0,.10% 0,.0109 
CD19 16 28948667 1% 0,.0109 
CLEC16A 16 11051758 0,.10% 0,.1743 
CLEC16A 16 11051758 1% 0,.4079 
CYBB X 37658219 0,.10% 0,.6885 
CYBB X 37658219 1% 0,.6885 
DNASE1L3 3 58179089 0,.10% 0,.6531 
DNASE1L3 3 58179089 1% 0,.6531 
IKZF1 7 50444387 0,.10% 0,.1164 
IKZF1 7 50444387 1% 0,.1164 
IRF7 11 613097 0,.10% 0,.4161 
IRF7 11 613097 1% 0,.4161 
JAZF1 7 27872484 0,.10% 0,.5979 
JAZF1 7 27872484 1% 0,.5979 
LYN 8 56863106 0,.10% 0,.2587 
LYN 8 56863106 1% 0,.2587 
MECP2 X 153296464 0,.10% 0,.0256 
MECP2 X 153296464 1% 0,.0256 
NFE2L2 2 178096309 0,.10% 0,.5976 
NFE2L2 2 178096309 1% 0,.0732 
PDHX 11 34938246 0,.10% 1,.0000 
PDHX 11 34938246 1% 1,.0000 
PHRF1 11 591436 0,.10% 0,.0527 
PHRF1 11 587372 1% 0,.1683 
PTPN22 1 114372222 0,.10% 0,.2984 
PTPN22 1 114372222 1% 0,.2984 
RASGRP3 2 33740227 0,.10% 0,.1167 
RASGRP3 2 33740227 1% 0,.1167 
RNASEH2C 11 65487277 0,.10% 0,.0252 
RNASEH2C 11 65487277 1% 0,.0252 
TMEM39A 3 119165965 0,.10% 0,.5948 
TMEM39A 3 119165965 1% 0,.5948 
TNXB 6 32009134 0,.10% 0,.1259 
TNXB 6 32009134 1% 0,.1060 
TRAF3IP2 6 111887757 0,.10% 0,.1163 
TRAF3IP2 6 111887757 1% 0,.2599 
TREX1 3 48508607 0,.10% 0,.5967 
TREX1 3 48508607 1% 0,.5967 
 65 
WDFY4 10 49933991 0,.10% 0,.2680 
WDFY4   1% 0,.6425 
 
A. B. Age/Sex distributionEthnicity
D. SLE cohort (n=117) E.  Control cohort 
Number of variants : 208 787
 (5020 individual variants)
 26 358
 (765 individual variants)






25 (22 ind. variants)
INDEL:




Algorithm to detect rare and predicted 
pathogenic variants
Next generation sequencing
146 genes  
28 KLC (Known Lupus Causing) = Monogenic lupus
118 PLC (Potentially Lupus Causing)
 = candidates from GWAS and mouse models
 










Known lupus-causing gene Potentionally lupus-causing gene
14 patients with 17 rare, predicted pathogenic 




















Number of variants : 30 955  (2126 individual variants)
 4081 including (462 individual variants)






21 (20 ind. variants)29 individuals
- Ethnicity matched 791 
unrelated controls (1000g)
- 574 controls (FREX) 
 
INDEL:
17 (15 ind. variants)
In house targeted exome sequencing
of the 146 genes 
Whole exome sequencing
Extraction of the 146 genes 

































Number of variants : 96883
 (3062 individual variants)
 4431







23 (21 ind. variants)
41 individuals









































































DNA binding domain                                                      Dimerization
WT/WT WT/D120V





Δ Ex5/ WTT97Ifs*2/ WT del exon 5      
T215Gfs*2
T97Ifs*2

















































































Gene number 1 2 3
Control 1000g (n = 791)
cSLE (n = 117)
A. B.
E. Combined frequency of KLC and PLC rare 
and predicted damaging variants per individual 
PLC-related  monoallelic variants 
SLE/controls






30 * * *
* * *
* * *
p = 1.33 x10
p = 0.03 p = 0.0084





































Total Rare Rare and 
pathogenic
























































































































KLC-related  monoallelic variants 
SLE/controls 
PLC-related  monoallelic variants 
SLE/controls
cSLE cSLE





A. Mendelian Lupus (n=8)
sex ratio = 1
Age at onset = 7
(SD +/- 4.4) 
B. Patients carrying variants in KLC genes  (n=7)
sex ratio = 1.33
Age at onset = 7
(SD +/- 3) 
C. Patients carrying variants in PLC genes (n=14)
sex ratio = 0.4
Age at onset = 10
(SD +/- 3 
D. Patients without filtered variants (n=88)
sex ratio = 0.17
Age at onset = 9
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